

## Coronavirus and COVID-19

### Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive

As of 15 January 2022, the following criteria apply to proof of vaccination as defined in the COVID-19 Protective Measures Exceptions Ordinance (SchAusnahmV).

**Changes to the criteria will be posted here as soon as reasonably possible.**

Pursuant to section 2 sentence 3 of the SchAusnahmV, proof of complete vaccination protection against the coronavirus SARS-CoV-2 exists if the underlying vaccinations correspond to the requirements published by the Paul-Ehrlich-Institut. These requirements, published in consultation with the Robert Koch-Institut and taking currently available medical information into account, must be met with respect to the following criteria:

- a) the vaccine used,
- b) the number of individual vaccinations required for complete vaccination protection,
- c) any booster vaccinations required for continued full vaccination protection,
- d) the length of time
  - a) that must pass after vaccination for complete vaccination protection and
  - b) that must not be exceeded between individual vaccinations and booster vaccinations.

The following vaccines can be used in the following combinations for full vaccination protection.

#### Requirements for full vaccination protection with a vaccine

Vaccine	Marketing Authorisation Holder	Number of vaccine doses for complete vaccination
Comirnaty Authorisation No. EU/1/20/1528	BioNTech Manufacturing GmbH	2
Spikevax Authorisation No. EU/1/20/1507	Moderna Biotech Spain, S.L.	2
Vaxzevria Authorisation No. EU/1/21/1529	AstraZeneca AB, Schweden	2
COVID-19 Vaccine Janssen Authorisation No. EU/1/20/1525	Janssen-Cilag International NV	2
Nuvaxovid Authorisation No. EU/1/21/1618	Novavax CZ a.s.	2

#### Requirements for complete vaccination protection with different vaccines (heterologous vaccination schedule)

Vaccination 1	Vaccination 2	Number of vaccine doses for complete vaccination
Vaxzevria Authorisation No. EU/1/21/1529	Comirnaty Authorisation No. EU/1/20/1528	2
Vaxzevria Authorisation No. EU/1/21/1529	Spikevax Authorisation No. EU/1/20/1507	2
Comirnaty Authorisation No. EU/1/20/1528	Spikevax Authorisation No. EU/1/20/1507	2
Spikevax Authorisation No. EU/1/20/1507	Comirnaty Authorisation No. EU/1/20/1528	2
COVID-19 Vaccine Janssen Authorisation No. EU/1/20/1525	Comirnaty Authorisation No. EU/1/20/1528	2
COVID-19 Vaccine Janssen Authorisation No. EU/1/20/1525	Spikevax Authorisation No. EU/1/20/1507	2

#### Time interval after vaccination for complete vaccination protection

Fourteen days must have passed since the last required vaccination in order for the vaccination to be considered complete.

## Exceptional circumstances justifying full vaccination protection with a single dose of vaccine

Notwithstanding the requirements above, a single dose of vaccine with any of the vaccines listed above is considered sufficient if

- the person concerned has physical or digital proof in German, English, French, Italian or Spanish of a positive antibody test carried out on them and this test was carried out at a time when the person concerned had **not yet received a vaccination** against COVID-19. The laboratory diagnostic findings must have come from a laboratory that works in accordance with the guidelines of the German Medical Association on Quality Assurance in Medical Laboratory Examinations (RiLiBÄK) or that is accredited in accordance with DIN EN ISO 15189. In this case, the 14-day post-vaccination period does not apply.
- the person concerned has proof of a previous infection with the SARS-CoV-2 coronavirus. Proof of infection requires proof of a test based on laboratory diagnostics using nucleic acid detection laboratory diagnostics (PCR, POC-PCR or other nucleic acid amplification technology methods) and this test must have been carried out at a time when the person concerned had **not yet been vaccinated** against COVID-19. If the infection occurred before the first vaccination was given, the required 14-day post vaccination period does not apply.
- the person concerned was infected with the SARS-CoV-2 coronavirus **after receiving a single vaccine dose**. Proof of infection requires proof of a test based on laboratory diagnostics using nucleic acid detection (PCR, POC-PCR or other nucleic acid amplification technology methods). If the infection occurred after the first vaccine dose was administered, 28 days must have passed since the infection was first detected.

### Note

**Information on booster vaccinations and the corresponding time intervals has not yet been published.**

### As of

10 March 2022

---

### Further Information

- › European Union - Re-Open EU: Overview of vaccines administered by third countries for which most EU Member States/EEA countries would waive travel restrictions (Excel file) [[https://reopen.europa.eu/static/COVID-19\\_VACCINES\\_3rd\\_countries\\_v2\\_05012022.xlsx](https://reopen.europa.eu/static/COVID-19_VACCINES_3rd_countries_v2_05012022.xlsx)]
- › Ordinance amending the Coronavirus Entry Ordinance of 1 March 2022 (German only) [<https://www.bundesanzeiger.de/pub/publication/d9JjQxZHLAox58JuSJ/content/d9JjQxZHLAox58JuSJ/BAnz%20AT%2002.03.2022%20V1.pdf?inline>]
- › Ordinance amending the COVID-19 Protective Measures Exceptions Ordinance and the Ordinance on Coronavirus Entry Regulations of 14 January 2022 (German only) [<https://www.bundesanzeiger.de/pub/publication/yW2hBRkcEPpvCQIb8IT/content/yW2hBRkcEPpvCQIb8IT/BAnz%20AT%2014.01.2022%20V1.pdf?inline>]

### Archive

- › Ordinance on the Regulation of Relief and Exemptions from Protective Measures to Prevent the Spread of COVID-19 (COVID-19 Protective Measures Exemptions Ordinance - SchAusnahmV) of 8 May 2021 (German only) [<https://www.bundesanzeiger.de/pub/publication/x6tHxtuQopora3FnUEG/content/x6tHxtuQopora3FnUEG/BAnz%20AT%2008.05.2021%20V1.pdf?inline>]
- › Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations (PDF, As of 15 January 2022) [[/SharedDocs/Downloads/EN/newsroom-en/dossiers/archive-proof-vaccination/proof-of-vaccination-covid-19-directives-as-of-15-january-2022.pdf?\\_\\_blob=publicationFile&v=3](#)]
- › Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations (PDF, As of 21 December 2021) [[/SharedDocs/Downloads/EN/newsroom-en/dossiers/archive-proof-vaccination/proof-of-vaccination-covid-19-directives-as-of-21-december-2021.pdf?\\_\\_blob=publicationFile&v=4](#)]

---

### Content

1. **Role of the Paul-Ehrlich-Institut** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=1](#)]
2. **COVID-19 Vaccines** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=2](#)]
3. **Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive**
4. **FAQ Coronavirus** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=4](#)]
5. **Biomedicines** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=5](#)]
6. **Safety of COVID-19 Vaccines** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=6](#)]
7. **Research Work** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=7](#)]
8. **SARS-CoV-2 Test Systems** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=07071F9C4D95E1F4FA9164B8B7E65C69.intranet241?nn=164146&cms\\_pos=8](#)]



The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health.  
Its research and control activities promote the quality, efficacy and safety of biological medicinal products.

© Paul-Ehrlich-Institut 2022